William V Bobo
Mayo Clinic · Consultant - Psychiatry · Vanderbilt University Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name William V Bobo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:23 UTC. Open this list on ClinicalTrials.gov
- N/ANCT04355650 · Augmented Human Intelligence in Major Depressive DisorderMayo Clinic · completed · Depression, Major Depressive Disorder · principal investigator
- Ph2NCT03290963 · Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving KetamineWilliam V. Bobo, M.D. · withdrawn · Treatment Resistant Depression · principal investigator
- Ph2NCT02094898 · Ketamine for Depression and Suicide RiskMayo Clinic · completed · Depression, Suicide · principal investigator
- Ph4NCT00373672 · Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective DisorderNorthwestern University · completed · Schizophrenia, Schizoaffective Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- SCH: Wearable Augmented Prediction of Burnout in Nurses: A Synergy of Engineering, Bioethics, NursingR01NR020362 · NINR · MAYO CLINIC ROCHESTER · fiscal years 2022 to 2025 · $299,998 awarded in 2025Same name and institution; not confirmed by an ID
- Understanding the Bidirectional Relationship between Depression and Heart FailureR01HS023077 · AHRQ · MAYO CLINIC ROCHESTER · fiscal years 2014 · $399,999 awarded in 2014Same name and institution; not confirmed by an ID
- Pharmacoepidemiology of Atypical Antipsychotic DrugsK23MH087747 · NIMH · MAYO CLINIC ROCHESTER · fiscal years 2010 to 2013 · $169,740 awarded in 2013Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:23 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.J Clin Psychiatry · 2008128 citationsRCR 4.8
- A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.J Clin Psychiatry · 2008122 citationsRCR 4.3
- Continuation phase intravenous ketamine in adults with treatment-resistant depression.J Affect Disord · 201678 citationsRCR 3.8
- Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE).Bipolar Disord · 201576 citationsRCR 3.4
- Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder.J Clin Psychiatry · 201657 citationsRCR 2.9
- 56 citationsRCR 2.4
- The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar Disord · 201551 citationsRCR 2.0
- Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder.J Affect Disord · 201349 citationsRCR 2.0
- Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.Am J Psychiatry · 201540 citationsRCR 1.8
- 37 citationsRCR 1.3